On January 18, 2022 NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, reported that Scott Carmer, Chief Executive Officer, will participate in the LLS TAP panel discussion entitled "Expanding the Possible with Next Generation Cell Therapies" on Friday, January 21, 2022 at 12:00 p.m. Eastern Time (Press release, NexImmune, 18 18, 2022, View Source [SID1234605598]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast will be accessible on the Investor Relations page of NexImmune’s website at Events and Presentations | NexImmune, Inc. Participants may also register at LLS TAP: Expanding the Possible with Next-Generation Cell Therapies.

LLS and NexImmune have a long history of working together. In October 2017, NexImmune benefitted from an initial TAP investment and in 2021 received a second investment as part of the Company’s initial public offering to support NexImmune’s ongoing Phase 1/2 studies in AML/MDS and multiple myeloma.

"We are excited with our continued support of NexImmune and their participation in this panel. The LLS track record in accelerating lifesaving blood cancer treatments is unparalleled," said Lee Greenberger, Ph.D., LLS Chief Scientific Officer. "The continuity of our funding from preclinical through clinical research demonstrates our commitment to supporting innovative therapies as they move from the laboratory into practice."